ISG15 as a Potent Immune Adjuvant in MVA-Based Vaccines Against Zika Virus and SARS-CoV-2

[Background] Vaccines represent one of the most affordable and efficient tools for controlling infectious diseases; however, the development of efficacious vaccines against complex pathogens remains a major challenge. Adjuvants play a relevant role in enhancing vaccine-induced immune responses. One...

ver descrição completa

Detalhes bibliográficos
Autores: García-Arriaza, Juan, Falqui, Michela, Pérez, Patricia, Coloma, Rocío, Perdiguero, Beatriz, Álvarez, Enrique, Marcos-Villar, Laura, Astorgano, David, Campaña Gómez, Irene, Sorzano, Carlos Óscar S., Esteban, Mariano, Gómez, Carmen E., Guerra, Susana
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/394177
Acesso em linha:http://hdl.handle.net/10261/394177
Access Level:acceso abierto
Palavra-chave:ISG15
Adjuvant
Vaccines
MVA
ZIKV
SARS-CoV-2
Innate immunity
T-cell responses
Descrição
Resumo:[Background] Vaccines represent one of the most affordable and efficient tools for controlling infectious diseases; however, the development of efficacious vaccines against complex pathogens remains a major challenge. Adjuvants play a relevant role in enhancing vaccine-induced immune responses. One such molecule is interferon-stimulated gene 15 (ISG15), a key modulator of antiviral immunity that acts both through ISGylation-dependent mechanisms and as a cytokine-like molecule.

Registos relacionados